Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors

被引：0
|
作者：
Annemiek van Ommen-Nijhof
Judy N. Jacobse
Lars C. Steggink
Joop D. Lefrandt
Jourik A. Gietema
Flora E. van Leeuwen
Michael Schaapveld
Gabe S. Sonke
机构：
[1] The Netherlands Cancer Institute,Department of Medical Oncology
[2] Leiden University Medical Center,Department of Radiotherapy
[3] Erasmus University Medical Center,Department of Medical Oncology
[4] University Medical Center Groningen,Department of Internal Medicine
[5] University Medical Center Groningen,Department of Medical Oncology
[6] The Netherlands Cancer Institute,Department of Psychosocial Research and Epidemiology
[7] The Netherlands Cancer Institute,Department of Medical Oncology
[8] University of Amsterdam,Department of Medical Oncology
来源：
Breast Cancer Research and Treatment | 2022年 / 196卷
关键词：
Breast cancer; Endocrine therapy; Aromatase inhibitor; Cardiovascular disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：591 / 602
页数：11
相关论文
共 50 条
  • [21] Vitamin D Insufficiency and Musculoskeletal Symptoms in Breast Cancer Survivors on Aromatase Inhibitor Therapy
    Waltman, Nancy L.
    Ott, Carol D.
    Twiss, Janice J.
    Gross, Gloria J.
    Lindsey, Ada M.
    CANCER NURSING, 2009, 32 (02) : 143 - 150
  • [22] Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer
    Buzdar, Aman U.
    Coombes, R. Charles
    Goss, Paul E.
    Winer, Eric P.
    CANCER, 2008, 112 (03) : 700 - 709
  • [23] Adjuvant aromatase inhibitor therapy: Outcomes and safety
    Janni, Wolfgang
    Hepp, Philip
    CANCER TREATMENT REVIEWS, 2010, 36 (03) : 249 - 261
  • [24] Safety of aromatase inhibitor therapy in breast cancer
    Lintermans, Anneleen
    Neven, Patrick
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (08) : 1201 - 1211
  • [25] Interventions for the Treatment of Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors
    Yang, Gee Su
    Kim, Hee Jun
    Griffith, Kathleen A.
    Zhu, Shijun
    Dorsey, Susan G.
    Renn, Cynthia L.
    CANCER NURSING, 2017, 40 (04) : E26 - E41
  • [26] Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
    Chen, Han
    Shao, Zhi-Ming
    Yu, Ke-Da
    Xu, Ge-Zhi
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (06)
  • [27] Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer
    van de Velde, C. J. H.
    Verma, S.
    van Nes, J. G. H.
    Masterman, C.
    Pritchard, K. I.
    CANCER TREATMENT REVIEWS, 2010, 36 (01) : 54 - 62
  • [28] Evaluating the Role of Extended Aromatase Inhibitor Therapy in Early Hormone-Positive Breast Cancer
    Vyas O.H.
    Kaklamani V.G.
    Current Breast Cancer Reports, 2017, 9 (3) : 183 - 187
  • [29] Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
    Butani, Dimple
    Gupta, Nidhi
    Jyani, Gaurav
    Bahuguna, Pankaj
    Kapoor, Rakesh
    Prinja, Shankar
    BREAST CANCER-TARGETS AND THERAPY, 2021, 13 : 625 - 640
  • [30] Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy
    Chavarri-Guerra, Y.
    Higgins, M. J.
    Szymonifka, J.
    Cigler, T.
    Liedke, P.
    Partridge, A.
    Ligibel, J.
    Come, S. E.
    Finkelstein, D.
    Ryan, P. D.
    Goss, P. E.
    BRITISH JOURNAL OF CANCER, 2014, 111 (11) : 2046 - 2050
12345